Navigation Links
Potential new therapeutic molecular target to fight cancer
Date:11/1/2007

Researchers at the Virginia Commonwealth University Massey Cancer Center have identified the enzyme sphingosine kinase 2 as a possible new therapeutic target to improve the efficacy of chemotherapy for colon and breast cancer.

In the Nov. 1 issue of the journal Cancer Research, researchers examined human colon and breast cancer cells and established a role of sphingosine kinase 2 (SphK2), an enzyme that forms the potent lipid mediator sphingosine-1-phosphate in the death of cancer cells mediated by the chemotherapeutic drug, doxorubicin.

Doxorubicin is able to kill cancer cells by working with p53, one of the most protective anti-cancer proteins in the human body. However, doxorubicin also relies on p53- independent mechanisms to induce death in colon and breast cancer cells.

Understanding how doxorubicin kills in a p53-independent manner is a major goal of cancer researchers because most cancer cells have mutated p53, said lead author Sarah Spiegel, Ph.D., chair and professor in the VCU Department of Biochemistry and Molecular Biology and co-leader of the cancer center's cancer cell biology program.

According to Spiegel, the study demonstrated that SphK2 is important for p53-independent induction of expression of p21, a cyclin-dependent kinase inhibitor. This p21 regulates the cell cycle, and apoptosis or programmed cell suicide, mediated by doxorubicin. Human colon and breast cancer cells were killed more efficiently by doxorubicin when SphK2 was removed from the cells.

Therefore, the findings suggest that SphK2 influences the balance between cytostasis, and apoptosis of human cancer cells, Spiegel said. Cytostasis refers to the stoppage of cellular growth and multiplication.

Spiegel said that cell death was induced by doxorubicin and decreased p21.

Spiegel, who is internationally recognized for her pioneering work on new lipid mediators that regulate cell growth and cell death, and her colleagues, first discovered the role of sphingosine-1-phosphate in cell growth regulation nearly a decade ago. Spiegel and her team are continuing this work to better understand the functions of these enzymes.


'/>"/>

Contact: Sathya Achia-Abraham
sbachia@vcu.edu
804-827-0890
Virginia Commonwealth University
Source:Eurekalert

Related biology news :

1. Novel Enzyme Shows Potential As An Anti-HIV Target
2. Potential Cure for Lymphoma in HIV patients
3. MetaChip provides quick, efficient toxicity screening of potential drugs
4. Simple drug has the potential to save many lives threatened by malaria
5. Potential treatments for neurofibromatosis
6. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
7. Potential Drug Target For Treating Cocaine Abuse Found
8. Scripps scientists find potential for catastrophic shifts in Pacific ecosystems
9. Engineers improve plastics potential for use in implants by linking it to biological material
10. Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory
11. Improving the potential of cancer vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... India , March 23, 2017 The report "Gesture ... Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, ... at a CAGR of 29.63% between 2017 and 2022. ... ... ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/13/2017)... March 13, 2017 Future of security: Biometric Face Matching ... ... DERMALOGs Face Matching enables to match face pictures against each ... to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching on ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... San Diego, CA (PRWEB) , ... April 20, 2017 , ... ... and management of clinical trials worldwide, announced today that they were named one of ... magazine , which covers the latest developments in the pharmaceutical industry. , “We take ...
(Date:4/20/2017)... 20, 2017 For today, Stock-Callers.com redirects ... drug development and clinical research aimed at treating diseases and ... BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: ... You can access our complimentary research reports on these stocks ... http://stock-callers.com/registration ...
(Date:4/19/2017)... (PRWEB) , ... April 18, 2017 , ... ... Halo Labs . The move comes after the company changed focus to ... market, our new brand and our new technology,” says CEO Robert Hart. Founders ...
(Date:4/19/2017)... Ca (PRWEB) , ... April 19, 2017 , ... ... Virtual Event, which makes educational webinars accessible to novices as well as ... of preanalytical variables of commonly performed coagulation screening tests. , Hemostasis testing ...
Breaking Biology Technology: